ASCO 2023 | Elucidating immunotherapy biomarkers for breast cancer

Justin Balko, PharmD, PhD, Vanderbilt University Medical Center, Nashville, TN, provides an overview of current efforts to discover novel immunotherapy biomarkers for breast cancer. Whilst not all patients will benefit from immunotherapy, novel biomarkers will enable the identification of patients who will respond to immunotherapy. Dr Balko additionally highlights the differential nature of immunotherapy-related adverse events. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.